Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S L Walmsley

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 1, 1990
In vitro susceptibility of "Campylobacter upsaliensis" to twenty-four antimicrobial agentsM A Preston, A E Simor, S L Walmsley, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1994
Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. Canadian Haemophilus Study GroupS R Scriver, S L Walmsley, C L Kau, et al.
The Journal of Infectious Diseases|July 7, 2000
Factors contributing to the lack of human immunodeficiency virus type 1 (HIV-1) transmission in HIV-1-discordant partnersD Bienzle, K S MacDonald, F M Smaill, et al.
HIV Medicine|February 11, 2014
Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation TrialJ E Lake, G A McComsey, T Hulgan, et al.
HIV Medicine|June 2, 2021
Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC)A Zhabokritsky, L Szadkowski, A N Burchell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 30, 1998
Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study GroupS D Shafran, J A Talbot, S Chomyc, et al.
AIDS Research and Human Retroviruses|July 20, 2001
Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cellsC M Tsoukas, H M Turner, G E Hatzakis, et al.
The New England Journal of Medicine|August 8, 1996
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study GroupS D Shafran, J Singer, D P Zarowny, et al.
Antiviral Research|January 2, 2007
Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtideM R Loutfy, J M Raboud, J S G Montaner, et al.
HIV Medicine|September 1, 2007
A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administrationM R Loutfy, M Harris, J M Raboud, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 1, 1990
In vitro susceptibility of "Campylobacter upsaliensis" to twenty-four antimicrobial agentsM A Preston, A E Simor, S L Walmsley, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1994
Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. Canadian Haemophilus Study GroupS R Scriver, S L Walmsley, C L Kau, et al.
The Journal of Infectious Diseases|July 7, 2000
Factors contributing to the lack of human immunodeficiency virus type 1 (HIV-1) transmission in HIV-1-discordant partnersD Bienzle, K S MacDonald, F M Smaill, et al.
HIV Medicine|February 11, 2014
Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation TrialJ E Lake, G A McComsey, T Hulgan, et al.
HIV Medicine|June 2, 2021
Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC)A Zhabokritsky, L Szadkowski, A N Burchell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 30, 1998
Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study GroupS D Shafran, J A Talbot, S Chomyc, et al.
AIDS Research and Human Retroviruses|July 20, 2001
Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cellsC M Tsoukas, H M Turner, G E Hatzakis, et al.
The New England Journal of Medicine|August 8, 1996
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study GroupS D Shafran, J Singer, D P Zarowny, et al.
Antiviral Research|January 2, 2007
Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtideM R Loutfy, J M Raboud, J S G Montaner, et al.
HIV Medicine|September 1, 2007
A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administrationM R Loutfy, M Harris, J M Raboud, et al.
Pageof 3